Seeking Alpha

The $7.9B that Abbott (ABT) earned from arthritis drug Humira last year could be at risk after...

The $7.9B that Abbott (ABT) earned from arthritis drug Humira last year could be at risk after Roche's (RHHBY.PK) Actemra performed better in a trial of patients who couldn't take methotrexate. In another study, Bristol-Myers' (BMY) Orencia performed as well as Humira in patients who hadn’t taken a biological rheumatoid arthritis treatment before.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs